MedTrace Logo

Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma

NCT00496587 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2017-07-19

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn if the combination of 3 drugs (gemcitabine, capecitabine, and bevacizumab) can help to control metastatic or unresectable renal cell carcinoma. The safety of this drug combination will also be tested.

Conditions

Interventions

DRUG

Capecitabine

800 mg/m\^2 By Mouth Twice Daily On Days 1-21.

DRUG

Gemcitabine

900 mg/m\^2 By Vein Over 30 Minutes on Days 1 and 15.

DRUG

Bevacizumab

10 mg/kg By Vein On Days 1 and 15.

Sponsors & Collaborators

Principal Investigators

  • Nizar M. Tannir, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00496587 on ClinicalTrials.gov